Pfizer’s latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean ...

PCV21 is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter a Phase III clinical trial in infants and toddlers. Sanofi and SK Bioscience announced that they have ...

If you haven’t received the pneumonia (pneumococcal) vaccine, you’re among the majority of Americans. Just one in four (25%) people at high risk of pneumococcal disease, an infection that ...

Before BMS’ offering, Roche’s PD-L1 inhibitor Tecentriq became the first checkpoint inhibitor to secure a subcutaneous approval from the FDA. Called Tecentriq Hybreza, the injection’s ...

for subcutaneous injection across approved nivolumab (Opdivo) indications for adult, solid tumors as monotherapy, monotherapy maintenance following completion of nivolumab plus ipilimumab (Yervoy ...

Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate ...

Table 2. A Provision of Aggregate and Serotype-Specific Vaccine Efficacy at Different Time Points Postvaccination and Model Coefficient Estimates VE C, % (95% CrI) at Several Time Points After ...

Today it is driving efforts to create a new generation of therapies known as “cancer vaccines” that aim to train the immune system to recognise tumours and fight their spread. Trials are now ...

Can you get a vaccine to prevent all cancers? Reports in Russia’s state-run news agency claimed this week that Russian scientists have developed an mRNA vaccine that has shown the ability to suppress ...

Separately, the analyst flagged Pfizer management’s mention of the fourth generation 25-valent pneumococcal vaccine (PCV), which management affirms continues to progress in Phase 2. Shibutani ...

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine program into phase 3. The move follows a phase 2 win last ...